Nesidioblastosis

Definition

• Diffuse beta-cell hypertrophy and islet hyperplasia
• Ectopic islet tissue
• Multiloculated islets
• Ductuloislet complexes (beta cells budding directly from pancreatic ducts)

Epidemiology and Clinical Forms

1. Neonatal / Congenital Form (Classic)

• Focal form - adenomatous hyperinsulinism (focal lesion amenable to partial resection)
• Diffuse form - diffuse hyperinsulinism (requires near-total pancreatectomy)

2. Adult-Onset Form (Acquired / Post-Bariatric)

3. Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS)

Clinical Features

• Lethargy, altered consciousness, generalized seizures
• Sweating, weakness, hunger, tremor, nausea, anxiety, palpitations
• Personality change (reported by family members)
• Weight gain (patients learn to eat continuously to prevent attacks)
• In adults: postprandial predominance (vs. fasting hypoglycemia in insulinoma)

Diagnosis

1. Symptoms during fasting (or postprandially in adult/NIPHS form)
2. Blood glucose < 3.0 mmol/L (< 50 mg/dL) at time of symptoms
3. Symptom relief with glucose administration

• Elevated serum insulin with inappropriately low blood glucose
• Elevated C-peptide (confirms endogenous insulin source; rules out factitious hypoglycemia)
• Insulin (µU/mL) : glucose (mg/dL) ratio > 0.5 in a fasting patient
• Absolute insulin > 5 µU/mL with blood glucose < 40 mg/dL in infants
• Impaired ketone body production (unlike other causes of hypoglycemia)

Management

Medical (First-line)

• IV dextrose (central line if high concentrations needed) - maintain glucose > 40 mg/dL
• Diazoxide 15 mg/kg/day - opens K-ATP channels, inhibits insulin secretion
• Somatostatin analogs (octreotide) - short-term use; reduces insulin secretion
• Glucocorticoids, glucagon, and frequent feeding as temporizing measures

Surgical

• Near-total (95%) pancreatectomy - resects distal pancreas including uncinate process, leaves a small rim adjacent to the duodenum; controls hypoglycemia in ~90%
• Total pancreatectomy - reserved for persistent/recurrent hypoglycemia after lesser resection
• Subtotal (80%) pancreatectomy is insufficient for diffuse disease - recurrent hypoglycemia risks hypoglycemic encephalopathy

• Selective partial pancreatectomy - preserves normal pancreatic tissue and function

• Preferred: Convert Roux-en-Y bypass to a procedure that restores normal intestinal nutrient flow (e.g., sleeve gastrectomy), or add a restriction element (adjustable gastric band) - addresses the incretin excess driving beta-cell proliferation
• Pancreatic resection alone (without revision of the bypass) is inadequate
• Partial/total pancreatectomy has been performed in severe cases

Complications of Treatment

• Post-resection transient hyperglycemia (expected, resolves)
• Diabetes mellitus - long-term risk, even after clinical remission (occurs in medically and surgically treated patients alike)
• Exocrine pancreatic insufficiency after extensive resection - requires oral enzyme replacement
• Long-term metabolic surveillance is mandatory for all treated patients

Differential Diagnosis of Hyperinsulinemic Hypoglycemia

• Quick Compendium of Clinical Pathology, Henry's Clinical Diagnosis; Goldman-Cecil Medicine

Recent Evidence (PubMed 2021-2026)

1. Dieterle et al., 2023 (PMID 37371827) - Comprehensive review of diffuse adult-onset nesidioblastosis/NIPHS, confirming it as a rare but important cause of hyperinsulinemic hypoglycemia in adults.
2. Sempoux & Klöppel, 2023 (PMID 37279235) - Reviews the evolution in terminology and pathological understanding from "nesidioblastosis" to current classifications of congenital and adult hyperinsulinism; highlights that the term nesidioblastosis itself is now considered imprecise for some conditions.
3. Sabi et al., 2024 (PMID 39619217) - Reviews genetic variations in K-ATP channel mutations underlying hyperinsulinemic hypoglycemia.

Note: Sempoux & Klöppel 2023 is worth consulting - modern pathology literature is moving toward replacing "nesidioblastosis" with more specific terms (congenital hyperinsulinism, focal vs. diffuse disease) based on the underlying genetic and morphologic substrate.

Semaglutide

Drug Class and Overview

Mechanism of Action

• Pancreatic beta cells
• Peripheral and central nervous system
• Heart and vasculature
• Kidney, lung, GI mucosa

1. Glucose-dependent insulin secretion from beta cells (enhanced when glucose is elevated; minimal effect at normal glucose - hence low hypoglycemia risk)
2. Glucagon suppression
3. Delayed gastric emptying
4. Central appetite suppression (CNS GLP-1R activation via arcuate nucleus/hypothalamus reduces food intake)
5. Reduced beta-cell apoptosis in culture models

• Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung, 16e, p. 1189

Formulations and Pharmacokinetics

Subcutaneous Semaglutide

• Protection from DPP-4 degradation
• Delayed renal clearance
• Half-life ~165-184 hours (approximately 1 week) - enabling once-weekly dosing
• Peak concentration at 1-3 days after injection

• 0.25 mg/week x 4 weeks → 0.5 mg/week → up to 1 mg or 2 mg/week

• 0.25 mg/week x 4 weeks → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg/week (maintenance)

Oral Semaglutide (Rybelsus / oral Wegovy)

• Oral bioavailability only 0.4-1% (hence much higher doses needed orally)
• Must be taken fasting with a small glass of water
• Patient must wait 30 minutes before eating, drinking, or taking other medications
• For T2DM: 3 mg/day x 4 weeks → 7 mg/day → 14 mg/day (max for glucose lowering)
• For obesity (oral Wegovy, approved December 2025): up to 25 mg/day
• Katzung, 16e, p. 1190; NEJM Clinician, December 2025

FDA-Approved Indications (as of 2026)

Efficacy Data

Glycemic Control (T2DM)

• HbA1c reduction: 1.0-1.6% (subcutaneous); ~1.0% (oral 14 mg)
• Weight loss in T2DM trials: 3-5 kg at standard doses
• Generally superior to other GLP-1RAs and DPP-4 inhibitors in head-to-head HbA1c reduction

Weight Loss (Obesity)

• STEP trials (semaglutide 2.4 mg SC): Mean weight loss ~13-15% of body weight over 68 weeks vs. ~2-3% placebo - far exceeding all prior anti-obesity medications
• Oral semaglutide 25 mg: significant weight reduction (approval based on OASIS trials)
• Goodman & Gilman notes: semaglutide reduced body weight by 13 kg vs. controls in obesity trials

Cardiovascular Outcomes

• 20% reduction in MACE vs. placebo (HR 0.80, 95% CI 0.72-0.90, p<0.001)
• Mean follow-up 39.8 months
• First cardiovascular outcomes trial showing benefit of a weight-loss drug in patients without diabetes

Heart Failure with Preserved EF (HFpEF)

• Significant improvement in KCCQ-CSS (symptoms): +7.5 points vs. placebo (p<0.0001)
• Body weight reduction: -8.4% vs. placebo (p<0.0001)
• 6-minute walk distance improved by +17.1 m
• Win ratio for hierarchical composite (death + HF events + KCCQ + 6MWD): 1.65
• C-reactive protein (inflammation marker) reduced: treatment ratio 0.64

Kidney Outcomes

Peripheral Artery Disease

• Significant improvement in maximum treadmill walking distance vs. placebo (ratio 1.13; p=0.0004)
• First evidence of functional benefit in PAD with a GLP-1 agonist

Adverse Effects

• Katzung, 16e; Sabiston Textbook of Surgery

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia type 2 (MEN2)
• Severe gastrointestinal disease (relative)
• Prior serious hypersensitivity to semaglutide

Drug Interactions and Special Populations

• Risk of hypoglycemia increases when combined with sulfonylureas or insulin - dose reduction of those agents may be required
• Delays absorption of oral medications taken concurrently (due to gastric emptying delay)
• Pregnancy: Not recommended; weight loss during pregnancy not desirable
• Renal impairment: Unlike exenatide, semaglutide does not require dose adjustment for renal impairment (minimal renal clearance)
• Hepatic impairment: No dose adjustment required

Place in Therapy (Current Guidelines)

• Cardiovascular disease is present or at high risk
• Weight loss is a goal
• Hypoglycemia avoidance is important

Recent Key Trials Summary

Important 2025-2026 updates: Oral semaglutide was approved for CV risk reduction in T2DM (October 2025) and for obesity at 25 mg/day (December 2025, marketed as "oral Wegovy"). Semaglutide's patent is set to expire in 2026, which may enable generic/biosimilar development. WHO issued guidance on GLP-1 therapies for obesity in late 2025.